Vikram Padmanabhan
Pulmonary Disease · Seattle, WANPI 1144457631
Payments from drug & device makers
Across 2 payments — averaging $33.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Harmony Biosciences LLC$34
- Boston Scientific$33
What the payments were for
- Food & beverage$68100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Harmony Biosciences LLC | 1 | $34 |
| Boston Scientific | 1 | $33 |
How this compares
$68 in reported general payments places this provider in the 30th percentile of 275 pulmonary disease providers in Washington.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 147 | $187,894 |
| Fasenra PenBenralizumab | 19 | $115,497 |
| Ambrisentan | 12 | $92,106 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 99 | $88,643 |
| Dupixent PenDupilumab | 22 | $88,319 |
| EliquisApixaban | 56 | $67,668 |
| Breo ElliptaFluticasone/Vilanterol | 106 | $61,909 |
| NucalaMepolizumab | 12 | $43,036 |
| Spiriva HandihalerTiotropium Bromide | 30 | $41,474 |
| Spiriva RespimatTiotropium Bromide | 37 | $29,806 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 20 | $24,542 |
| Incruse ElliptaUmeclidinium Bromide | 36 | $21,628 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 24 | $20,901 |
| DuleraMometasone/Formoterol | 21 | $20,830 |
| SymbicortBudesonide/Formoterol Fumarate | 58 | $19,814 |
Paid to pharmacies, not to this prescriber.
Other pulmonary disease in Seattle
- Peter ChenSeattle$2.7M
- Pradeep SinghSeattle$1.1M
- Moira AitkenSeattle$700K
- Christopher GossSeattle$487K
- Anthony GerbinoSeattle$448K
- Lawrence HoSeattle$445K
- Suha KaduraSeattle$432K
- Amy DickeySeattle$305K
- Guang-Shing ChengSeattle$239K
- Jed GordenSeattle$236K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.